HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

Cresco Labs CRLBF, +11.29% was rallying by 9.4%, Green Thumb Industries GTBIF, +16.22% was up by 10.5% and Trulieve Cannabis TCNNF, +21.41% was up by 13.7%. During a Senate hearing in March, Garland reiterated a statement he made at his confirmation hearing that the Justice Department’s position on cannabis will be “very close to what was done” in the Cole memorandum, which was a policy put in place in 2013 that limited the role of federal law-enforcement regarding cannabis.

It’s also widely agreed that the Food and Drug Administration would be poised to regulate cannabis, but uncertainties remain over what that would look like, Zuanic said.

Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Pot stocks rally after health officials ask DEA to reclassify marijuana as lower-risk drugAssistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a schedule III substance.
Herkunft: FoxBusiness - 🏆 458. / 53 Weiterlesen »